GlassScriptPhysician profile
Parker L Bell
NPI 1619171188
$5,310.86
in general payments reported to CMS, 2019-2025
20 companies · $1,409 in 2025
The $1,409 reported for 2025 was more than what 91% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $657 · 2020: $624 · 2021: $397 · 2022: $598 · 2023: $700 · 2024: $925 · 2025: $1,409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,034.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,034.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,868.10 | 2019-2025 | Eterna, Proclaim, Octrode |
| Abbvie INC. | $556.86 | 2022-2025 | Botox |
| Biotronik Nro, INC. | $429.27 | 2025 | Prospera |
| Medtronic, INC. | $364.83 | 2021-2025 | Intellis Adaptivestim, Inceptiv |
| Allergan, INC. | $238.24 | 2019-2022 | |
| Boston Scientific Corporation | $189.00 | 2019-2022 | |
| Merz Pharmaceuticals, LLC | $145.69 | 2022-2024 | Xeomin |
| Medtronic USA, INC. | $107.13 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $88.02 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $68.70 | 2022-2023 | Seglentis |
| Pacira Therapeutics, INC. | $47.69 | 2019 | |
| Ferring Pharmaceuticals INC. | $40.59 | 2021-2023 | Euflexxa |
| Coloplast Corp | $35.26 | 2023-2024 | Porges Coloplast |
| Forte Bio-Pharma LLC | $33.66 | 2024 | Prolate, Nalocet |
| Daiichi Sankyo INC. | $20.71 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $17.68 | 2023 | Qutenza |
| Takeda Pharmaceuticals U.S.A., INC. | $17.02 | 2021 | |
| Mission Pharmacal Company | $15.93 | 2024 | Uribel Tabs |
| Pfizer INC. | $15.21 | 2019 | |
| Bioventus LLC | $11.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parker Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.